-
Revenue from operations: ₹1,124.95 crore for the quarter ended 30 June 2026
-
Total income (including other income): ₹1,239.58 crore
-
Profit before tax: ₹149.48 crore, delivering an operating margin of roughly 13.3 % of revenue
-
EBITDA (PBT + depreciation + finance costs): ₹231.57 crore, giving an EBITDA margin of about 20.6 %
-
Net profit after tax: ₹113.48 crore
-
Basic & diluted EPS: ₹0.85 per share
-
Other comprehensive loss (net of tax): (₹5.00 crore), resulting in total comprehensive income of ₹108.48 crore
-
The company operates in a single segment; no segment‑specific disclosures were required.
Piramal Pharma Limited (NSE: PPLPHARMA, BSE: 543635)
Frism is a financial information and news discovery platform. We provide factual summaries and data correlations for educational and informational purposes only. Frism does not provide investment advice, buy/sell recommendations, or directional market outlooks. Users should consult a qualified financial advisor before making any investment decisions.
Frism Computing (OPC) Private Limited
#74, 15TH CROSS, JP Nagar III Phase, Bangalore South, Bangalore 560078, Karnataka